Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

1,407

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

April 7, 2021

Study Completion Date

April 7, 2021

Conditions
COVID-19Viral Respiratory Illnesses
Interventions
DRUG

Nitazoxanide

Nitazoxanide 600 mg administered orally twice daily for six weeks

DRUG

Placebo

Placebo administered orally twice daily for six weeks

DIETARY_SUPPLEMENT

Vitamin Super B-Complex

Vitamin Super B-Complex administered orally twice daily to maintain the blind

Trial Locations (26)

10022

The New York Center for Travel and Tropical Medicine, New York

10456

RH Medical Urgent Care Professional PLLC, The Bronx

11229

Integrative Clinical Trials LLC, Brooklyn

32801

Clinical Neuroscience Solutions, Inc., Orlando

33165

New Horizon Research Center, Miami

33308

Invesclinica US LLC, Fort Lauderdale

33511

Meris Clinical Research, Brandon

33606

Tampa General Hospital, Tampa

33782

DMI Research, Pinellas Park

34744

The Chappel Group Research, Kissimmee

48124

Vida Clinical Studies, Dearborn

60429

Chicago Medical Research, LLC, Hazel Crest

60607

Chicago Clinical Research Institute, Inc., Chicago

Chicago Medical Research Institute, Inc., Chicago

60643

Quad Clinical Research, Chicago

68025

Beacom Family Health Connection, Fremont

70601

Centex Studies, Inc., Lake Charles

71913

HealthStar Research LLC, Hot Springs

75149

SMS Clinical Research LLC, Mesquite

77058

Centex Studies, Inc., Houston

77584

LinQ Research LLC, Pearland

78249

BFHC Research, San Antonio

78577

Rio Grande Valley Clinical Research Institute, Pharr

90806

Long Beach Clinical Trials, LLC, Long Beach

92647

So Cal Clinical Research, Huntington Beach

07103

North Jersey Community Research Initiative, Newark

All Listed Sponsors
lead

Romark Laboratories L.C.

INDUSTRY

NCT04359680 - Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter